Fmr LLC Has $101.40 Million Holdings in Eli Lilly And Co (LLY)
Fmr LLC raised its stake in Eli Lilly And Co (NYSE:LLY) by 172.9% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,188,301 shares of the company’s stock after acquiring an additional 752,864 shares during the period. Fmr LLC owned approximately 0.11% of Eli Lilly And Co worth $101,398,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. Bay Colony Advisory Group Inc d b a Bay Colony Advisors acquired a new position in Eli Lilly And Co in the 2nd quarter valued at $114,000. Legacy Advisors LLC raised its holdings in shares of Eli Lilly And Co by 118.0% during the 2nd quarter. Legacy Advisors LLC now owns 1,354 shares of the company’s stock worth $116,000 after buying an additional 733 shares in the last quarter. Fort L.P. acquired a new position in shares of Eli Lilly And Co during the 2nd quarter worth $121,000. Financial Management Professionals Inc. acquired a new position in shares of Eli Lilly And Co during the 2nd quarter worth $128,000. Finally, Twin Tree Management LP raised its holdings in shares of Eli Lilly And Co by 97.9% during the 2nd quarter. Twin Tree Management LP now owns 1,589 shares of the company’s stock worth $136,000 after buying an additional 786 shares in the last quarter. 76.17% of the stock is owned by hedge funds and other institutional investors.
In other Eli Lilly And Co news, major shareholder Lilly Endowment Inc sold 174,696 shares of the company’s stock in a transaction dated Wednesday, October 17th. The stock was sold at an average price of $113.25, for a total value of $19,784,322.00. Following the completion of the transaction, the insider now owns 119,005,804 shares of the company’s stock, valued at approximately $13,477,407,303. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, major shareholder Eli & Co Lilly sold 700,000 shares of the company’s stock in a transaction dated Tuesday, November 6th. The stock was sold at an average price of $14.00, for a total value of $9,800,000.00. Following the completion of the transaction, the insider now directly owns 3,148,647 shares of the company’s stock, valued at approximately $44,081,058. The disclosure for this sale can be found here. In the last ninety days, insiders sold 1,881,684 shares of company stock valued at $133,274,076. Insiders own 0.11% of the company’s stock.
Eli Lilly And Co (NYSE:LLY) last issued its earnings results on Tuesday, November 6th. The company reported $1.39 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.35 by $0.04. Eli Lilly And Co had a return on equity of 44.13% and a net margin of 1.85%. The business had revenue of $6.06 billion during the quarter, compared to analysts’ expectations of $6.04 billion. During the same quarter in the prior year, the firm earned $1.05 EPS. The business’s revenue for the quarter was up 7.1% compared to the same quarter last year. As a group, research analysts forecast that Eli Lilly And Co will post 5.57 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Monday, December 10th. Shareholders of record on Thursday, November 15th will be issued a $0.5625 dividend. The ex-dividend date of this dividend is Wednesday, November 14th. This represents a $2.25 dividend on an annualized basis and a yield of 2.01%. Eli Lilly And Co’s payout ratio is presently 52.57%.
A number of research firms have recently commented on LLY. Cantor Fitzgerald set a $100.00 price target on Eli Lilly And Co and gave the stock a “buy” rating in a report on Tuesday, July 24th. Societe Generale set a $106.00 price target on Eli Lilly And Co and gave the stock a “hold” rating in a report on Wednesday. ValuEngine cut Eli Lilly And Co from a “buy” rating to a “hold” rating in a report on Tuesday. Credit Suisse Group set a $84.00 price target on Eli Lilly And Co and gave the stock a “hold” rating in a report on Friday, July 13th. Finally, TheStreet raised Eli Lilly And Co from a “c+” rating to a “b+” rating in a report on Tuesday. Nine investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $111.19.
COPYRIGHT VIOLATION NOTICE: This news story was posted by Daily Political and is owned by of Daily Political. If you are accessing this news story on another site, it was copied illegally and republished in violation of United States & international copyright & trademark laws. The correct version of this news story can be viewed at https://www.dailypolitical.com/2018/11/10/fmr-llc-has-101-40-million-holdings-in-eli-lilly-and-co-lly.html.
Eli Lilly And Co Company Profile
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Read More: How analysts view the yield curve
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.